Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ZYNE | Zynerba Pharmaceuticals Inc

Index- P/E- EPS (ttm)-0.80 Insider Own5.51% Shs Outstand53.94M Perf Week-5.93%
Market Cap68.50M Forward P/E- EPS next Y-0.63 Insider Trans-1.62% Shs Float50.97M Perf Month-3.79%
Income-37.58M PEG- EPS next Q-0.20 Inst Own19.43% Short Float / Ratio0.46% / 0.24 Perf Quarter285.32%
Sales0.00M P/S- EPS this Y-3.96% Inst Trans-0.82% Short Interest0.23M Perf Half Y202.38%
Book/sh0.54 P/B2.36 EPS next Y26.39% ROA-69.93% Target Price3.17 Perf Year54.88%
Cash/sh0.67 P/C1.90 EPS next 5Y- ROE-87.13% 52W Range0.25 - 1.40 Perf YTD139.62%
Dividend- P/FCF- EPS past 5Y19.83% ROI-129.50% 52W High-9.29% Beta1.32
Dividend %- Quick Ratio3.41 Sales past 5Y-20.00% Gross Margin- 52W Low408.00% ATR0.04
Employees27 Current Ratio3.41 Sales Q/Q- Oper. Margin0.00% RSI (14)56.43 Volatility3.20% 2.29%
OptionableYes Debt/Eq0.01 EPS Q/Q9.71% Profit Margin- Rel Volume1.33 Prev Close1.28
ShortableYes LT Debt/Eq0.00 EarningsAug 14 BMO Payout- Avg Volume971.21K Price1.27
Recom3.00 SMA20-4.48% SMA5032.96% SMA200120.44% Volume1,294,035 Change-0.78%
Date Action Analyst Rating Change Price Target Change
Dec-21-20Reiterated H.C. Wainwright Buy $12 → $9
Jul-01-20Downgrade Needham Buy → Hold
Dec-31-19Resumed ROTH Capital Buy $12
Oct-21-19Initiated Needham Buy $18
Apr-22-19Resumed Canaccord Genuity Buy
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Today 08:00AM
Sep-25-23 10:41AM
Sep-14-23 11:01PM
Aug-14-23 11:06AM
09:02AM Loading…
Aug-08-23 04:05PM
Jul-25-23 05:18PM
Jun-29-23 12:00PM
Jun-28-23 04:05PM
Jun-20-23 07:00AM
Jun-13-23 04:05PM
May-23-23 07:00AM
May-18-23 10:05AM
07:12AM Loading…
May-15-23 07:12AM
Apr-12-23 07:30AM
Apr-05-23 07:30AM
Mar-28-23 07:35AM
Mar-13-23 04:15PM
Mar-07-23 07:00AM
Mar-01-23 07:00AM
Jan-11-23 08:30AM
Jan-08-23 09:56AM
Dec-21-22 07:29AM
Dec-05-22 07:30AM
Nov-29-22 07:00AM
07:30AM Loading…
Nov-28-22 07:30AM
Nov-15-22 07:30AM
Nov-14-22 07:30AM
Nov-02-22 07:30AM
Oct-17-22 07:00AM
Oct-10-22 07:00AM
Oct-06-22 07:00AM
Sep-29-22 07:00AM
Sep-22-22 07:00AM
Sep-08-22 09:15AM
Sep-06-22 07:00AM
Aug-31-22 07:00AM
Aug-10-22 07:00AM
Aug-03-22 07:00AM
Aug-01-22 07:11AM
Jul-21-22 07:00AM
Jul-07-22 07:00AM
Jun-24-22 01:19PM
Jun-22-22 10:39AM
Jun-21-22 08:05PM
Jun-01-22 07:00AM
May-24-22 07:00AM
May-17-22 07:00AM
May-16-22 07:00AM
May-11-22 01:30PM
May-09-22 04:57PM
May-02-22 07:00AM
Apr-21-22 07:00AM
Apr-05-22 07:00AM
Mar-22-22 07:00AM
Mar-08-22 10:00AM
Mar-04-22 02:34PM
Mar-01-22 06:00AM
Feb-28-22 04:05PM
Feb-22-22 05:13AM
Feb-15-22 07:00AM
Feb-10-22 07:00AM
Jan-06-22 07:00AM
Jan-05-22 06:29AM
Jan-04-22 04:05PM
Dec-06-21 07:00AM
Nov-22-21 07:00AM
Nov-15-21 07:00AM
Oct-21-21 07:00AM
Oct-19-21 04:15PM
Oct-08-21 07:30AM
Sep-20-21 07:00AM
Sep-13-21 07:00AM
Sep-09-21 11:06AM
Sep-07-21 07:00AM
Sep-02-21 07:30AM
Aug-09-21 07:00AM
Aug-04-21 07:30AM
Aug-02-21 01:31PM
Jul-07-21 07:30AM
Jun-30-21 07:00AM
Jun-29-21 09:01AM
Jun-11-21 02:44PM
Jun-09-21 04:05PM
Jun-07-21 08:00AM
Jun-04-21 07:30AM
Jun-03-21 10:00AM
May-27-21 07:30AM
May-26-21 07:30AM
May-17-21 08:00AM
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANIDO ARMANDOChairman & Chief Exec. OfficerSep 13Sale1.3317,83023,637936,722Sep 14 04:13 PM
Sebree Terri BPresidentSep 13Sale1.3312,40116,440596,241Sep 14 04:14 PM
Fickenscher James EChief Financial OfficerSep 13Sale1.338,99811,929378,087Sep 14 04:13 PM
Rosenberger BrianVP, Commercial & Business Dev.Sep 13Sale1.336,4118,499249,559Sep 14 04:14 PM
Jones Kenneth TSee RemarksSep 13Sale1.332,5053,32185,520Sep 14 04:13 PM
KISNER DANIEL LDirectorJun 14Sale0.351154075,778Jun 15 04:29 PM
MOCH KENNETH IDirectorJun 14Sale0.351154075,778Jun 15 04:30 PM
Stephenson PamelaDirectorJun 14Sale0.351154075,778Jun 15 04:30 PM
COOPER WARREN DDirectorJun 14Sale0.351154075,778Jun 15 04:28 PM
Butler John P.DirectorJun 14Sale0.351154080,765Jun 15 04:28 PM
FEDERICI WILLIAM JDirectorJun 14Sale0.351154075,778Jun 15 04:29 PM
Parker Albert PChief Legal OfficerFeb 15Sale0.543,1731,719227,018Feb 17 04:21 PM
ANIDO ARMANDOChairman & Chief Exec. OfficerJan 23Sale0.6035,45321,194576,235Jan 25 05:25 PM
Sebree Terri BPresidentJan 23Sale0.6024,66114,742343,204Jan 25 05:29 PM
Fickenscher James EChief Financial OfficerJan 23Sale0.6017,76910,622154,736Jan 25 05:28 PM
Rosenberger BrianVP, Commercial & Business Dev.Jan 23Sale0.6012,6637,57094,848Jan 25 05:26 PM